Cited by 526Chromatin Remodeling and CancerPARP inhibition in cancer therapyDNA Repair Mechanisms

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Open access

Shen, Jianfeng, Peng, Yang, Wei, Leizhen, Zhang, Wei, Yang, Lin, Lan, Li, Kapoor, Prabodh, Ju, Zhenlin, Mo, Qianxing, Shih, Ie-Ming, Uray, Ivan P., Wu, Xiangwei, Brown, Powel H., Shen, Xuetong, Mills, Gordon B., Peng, Guang·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-14-0849PMC PMC4497871

Published version of a preprint

Open this paper in CoChat — free account

Abstract

ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. In this article, we report a key function of ARID1A in regulating the DNA damage checkpoint. ARID1A is recruited to DNA double-strand breaks (DSB) via its interaction with the upstream DNA damage checkpoint kinase ATR. At the molecular level, ARID1A facilitates efficient processing of DSB to single-strand ends and sustains DNA damage signaling. Importantly, ARID1A deficiency sensitizes cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with ARID1A-mutant tumors. Significance: ARID1A has been identified as one of the most frequently mutated genes across human cancers. Our data suggest that clinical utility of PARP inhibitors might be extended beyond patients with BRCA mutations to a larger group of patients with ARID1A-mutant tumors, which may exhibit therapeutic vulnerability to PARP inhibitors. Cancer Discov; 5(7); 752–67. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 681

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-0849

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes
Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693
Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo
Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798

Flagged first, then by citations

Show all 61 references

Sorted by citations

Items 201–300 of 526

Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review
Corallo, S., Lasagna, A., Filippi, B., Alaimo, D., Tortorella, A., Serra, F., Vanoli, A., & Pedrazzoli, P. (2024) · Pathogens · doi:10.3390/pathogens13090728 · Cited by 27
Genomics of gynaecological carcinosarcomas and future treatment options
Barker, H. E., & Scott, C. L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.006 · Cited by 23
ARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 While ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition
Kurz, L., Miklyaeva, A., Skowron, M. A., Overbeck, N., Poschmann, G., Becker, T. K., Eul, K., Kurz, T., Schönberger, S., Calaminus, G., et al. (2020) · Cancers · doi:10.3390/cancers12040905 · Cited by 24
Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
Küemmel, S., Harrach, H., Schmutzler, R. K., Kostara, A., Ziegler-Löhr, K., Dyson, M. H., Chiari, O., & Reinisch, M. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00174-9 · Cited by 23
Primary Renal Synovial Sarcoma and Clinical and Pathological Findings: a Systematic Review
Blas, L., & Roberti, J. E. (2021) · Current Urology Reports · doi:10.1007/s11934-021-01038-w · Cited by 22
Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma
Mondello, P., Ansell, S. M., & Nowakowski, G. S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.826594 · Cited by 23
Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care
Casolino, R., Corbo, V., Beer, P. A., Hwang, C., Paiella, S., Silvestri, V., Ottini, L., & Biankin, A. V. (2022) · Cancers · doi:10.3390/cancers14133239 · Cited by 24
A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations
Stružinská, I., Hájková, N., Hojny, J., Krkavcová, E., Michálková, R., Dvořák, J., Němejcová, K., Matěj, R., Laco, J., Drozenová, J., et al. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01358-0 · Cited by 22
Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency
Kristeleit, R. S., Miller, R. E., & Kohn, E. C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159086 · Cited by 23
Associations Between Loss of ARID1A Expression and Clinicopathologic and Genetic Variables in T1 Early Colorectal Cancer
Kishida, Y., Oishi, T., Sugino, T., Shiomi, A., Urakami, K., Kusuhara, M., Yamaguchi, K., Kitagawa, Y., & Ono, H. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz062 · Cited by 22
The effects of ARID1A mutation in gastric cancer and its significance for treatment
Lü, S., Duan, R., Liang, C., & Song, Y. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03154-8 · Cited by 23
The rise of genomic profiling in ovarian cancer
Previs, R. A., Sood, A. K., Mills, G. B., & Westin, S. N. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1259069 · Cited by 23
Self-citation
PARP inhibitors as precision medicine for cancer treatment
Du, Y., Yamaguchi, H., Hsu, J. L., & Hung, M. (2017) · National Science Review · doi:10.1093/nsr/nwx027 · Cited by 20
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
Osoegawa, A., Gills, J. J., Kawabata, S., & Dennis, P. A. (2017) · Oncotarget · doi:10.18632/oncotarget.19667 · Cited by 21
CRISPR/Cas9-Mediated Gene Knockout of ARID1A Promotes Primary Progesterone Resistance by Downregulating Progesterone Receptor B in Endometrial Cancer Cells
Wang, H., Tang, Z., Li, T., Liu, M., Li, Y., & Xing, B. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504019x15561873320465 · Cited by 21
Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication
Hung, Y., Hsu, M., Chen, L., Hung, W., & Pan, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060903 · Cited by 22
Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma
Ge, H., Xiao, Y., Qin, G., Gu, Y., Xu, C., Jiang, W., Tu, X., Yang, W., & Bi, R. (2021) · Diagnostic Pathology · doi:10.1186/s13000-021-01071-w · Cited by 22
ARID1 Proteins: from Transcriptional and Post-Translational Regulation to Carcinogenesis and Potential Therapeutics
Odnokoz, O., Wavelet-Vermuse, C., Hophan, S. L., Bulun, S. E., & Wan, Y. (2021) · Epigenomics · doi:10.2217/epi-2020-0414 · Cited by 23
Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis
Ferri-Borgogno, S., Barui, S., McGee, A. M., Griffiths, T., Singh, P. K., Piett, C. G., Ghosh, B., Bhattacharyya, S., Singhi, A., Pradhan, K., et al. (2020) · Cancers · doi:10.3390/cancers12092695 · Cited by 22
Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Sirohi, D., Schmidt, R. L., Aisner, D. L., Behdad, A., Betz, B. L., Brown, N. A., Coleman, J. F., Corless, C. L., Deftereos, G., Ewalt, M. D., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.10.010 · Cited by 21
ARID1A ‐deficient cells require HDAC6 for progression of endometrial carcinoma
Megino‐Luque, C., Sisó, P., Mota‐Martorell, N., Navaridas, R., de la Rosa, I., Urdanibia, I., Albertí‐Valls, M., Santacana, M., Pinyol, M., Bonifaci, N., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13193 · Cited by 20
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium
Jackson, C. G., Moore, K. N., Cantrell, L. A., Erickson, B. K., Duska, L., Richardson, D. L., Landrum, L. M., Holman, L. L., Walker, J. L., Mannel, R. S., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.04.016 · Cited by 20
LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling
Shi, C.-J., Xue, Z.-H., Zeng, W.-Q., Deng, L.-Q., Pang, F., Zhang, F., Fu, W.-M., & Zhang, J. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00595-1 · Cited by 20
Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment
Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 21
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
Wenzl, K., Stokes, M. E., Novak, J. P., Bock, A. M., Khan, S., Hopper, M. A., Krull, J. E., Dropik, A. R., Walker, J. S., Sarangi, V., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01080-0 · Cited by 24
High‐level expression of ARID 1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy
Lin, Y., Tseng, I.-J., Kuo, C., Lin, H., Chiu, I., & Chiu, H. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13551 · Cited by 20
The clinical significance of PD-L1 in advanced gastric cancer is dependent onARID1Amutations and ATM expression
Buglioni, S., Melucci, E., Sperati, F., Pallocca, M., Terrenato, I., Nicola, F. D., Goeman, F., Casini, B., Amoreo, C. A., Gallo, E., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1457602 · Cited by 20
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma
Khalique, S., Nash, S., Mansfield, D., Wampfler, J., Attygalle, A. D., Vroobel, K. M., Kemp, H., Buus, R., Cottom, H., Roxanis, I., et al. (2021) · Cancers · doi:10.3390/cancers13153854 · Cited by 22
Targeting deficient DNA damage repair in gastric cancer
Young, K., Starling, N., & Cunningham, D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1217992 · Cited by 20
Cholangiocarcinoma: investigations into pathway-targeted therapies
Ntanasis‐Stathopoulos, I., Tsilimigras, D. I., Gavriatopoulou, M., Schizas, D., & Pawlik, T. M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1807333 · Cited by 19
Loss of ARID1A Promotes Hepatocellular Carcinoma Progression via Up-regulation of MYC Transcription
Xiao, Y., Liu, G., Ouyang, X., Zhai, D.-G., Zhou, J., Li, X., Zhang, Q., & Zhao, J. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00111 · Cited by 19
BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage
He, D.-D., Shang, X.-Y., Wang, N., Wang, G.-X., He, K.-Y., Wang, L., & Han, Z.-G. (2022) · Oncogene · doi:10.1038/s41388-022-02176-2 · Cited by 21
Inhibition of Arid1a increases stem/progenitor cell-like properties of liver cancer
Wang, L., Deng, C.-H., Luo, Q., Su, X., Shang, X., Song, S., Cheng, S., Qu, Y.-L., Zou, X., Shi, Y. Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215869 · Cited by 19
PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality
Yakovlev, V. A., Sullivan, S. A., Fields, E. C., & Temkin, S. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1124147 · Cited by 18
Extracranial metastasis of brain glioblastoma outside CNS : Pathogenesis revisited
Kurdi, M. E., Baeesa, S. S., Okal, F. M., Bamaga, A. K., Faizo, E., Fathaddin, A., Alkhotani, A., Karami, M. M., & Bahakeem, B. (2023) · Cancer Reports · doi:10.1002/cnr2.1905 · Cited by 19
Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma
Marks, E. I., Brown, V. S., & Dizon, D. S. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000641 · Cited by 19
Precision medicine for ovarian clear cell carcinoma based on gene alterations
Kuroda, T., & Kohno, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01622-z · Cited by 19
Role and potential clinical utility of ARID1A in gastrointestinal malignancy
Wang, R., Chen, M., Ye, X., & Poon, K. (2020) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2020.108360 · Cited by 20
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment
Genta, S., Martorana, F., Stathis, A., & Colombo, I. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103539 · Cited by 20
Relevance of ARID1A Mutations in Endometrial Carcinomas
Leo, A. D., Ravegnini, G., Musiani, F., Maloberti, T., Visani, M., Sanza, V., Angelini, S., Perrone, A. M., Iaco, P. D., Corradini, A. G., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12030592 · Cited by 18
Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma
Jung, U. S., Min, K., Kim, D., Kwon, M. J., Park, H., & Jang, H. S. (2020) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2021.32.e3 · Cited by 17
Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology
Shah, S. M., Demidova, E. V., Lesh, R. W., Hall, M. J., Daly, M. B., Meyer, J. E., Edelman, M. J., & Arora, S. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102337 · Cited by 17
Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy
Xu, S., Sak, A., Niedermaier, B., Erol, Y. B., Groneberg, M., Mladenov, E., Kang, M., Iliakis, G. E., & Stuschke, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.999626 · Cited by 17
Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective
Lebedev, T. D., Kousar, R., Patrick, B., Usama, M., Lee, M.-K., Tan, M., & Li, X. (2023) · Cells · doi:10.3390/cells12060952 · Cited by 17
Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy
Shi, Y., & Shin, D. S. (2023) · Biomolecules · doi:10.3390/biom13060984 · Cited by 17
Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study
Cramer, S., Miller, A. L., Pressey, J. G., Gamblin, T. L., Beierle, E. A., Kulbersh, B. D., Garcia, P. L., Radhakrishnan, R., Hendrix, S. V., Kelly, D. R., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2017.00327 · Cited by 18
Comprehensive Immunohistochemical Study of the SWI/SNF Complex Expression Status in Gastric Cancer Reveals an Adverse Prognosis of SWI/SNF Deficiency in Genomically Stable Gastric Carcinomas
Glückstein, M., Dintner, S., Arndt, T. T., Vlasenko, D., Schenkirsch, G., Agaimy, A., Müller, G., Märkl, B., & Grosser, B. (2021) · Cancers · doi:10.3390/cancers13153894 · Cited by 16
Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
Cerniglia, M., Xiu, J., Grothey, A., Pishvaian, M. J., Baca, Y., Hwang, J. J., Marshall, J. L., VanderWalde, A. M., Shields, A. F., Lenz, H.-J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0879 · Cited by 17
Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis)
Wang, Z., Zhang, X., Luo, Y., Song, Y., Xiang, C., He, Y., Wang, K., Yu, Y., Wang, Z., Peng, W., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06751-1 · Cited by 16
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study
Groß, E., van Tinteren, H., Li, Z., Raab, S., Meul, C., Avril, S., Laddach, N., Aubele, M. M., Propping, C., Gkazepis, A., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2848-2 · Cited by 15
Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer.
Zou, J., Qin, W., Yang, L., Wang, L., Wang, Y., Shen, J., Xiong, W., Yu, S., Song, S., Ajani, J. A., et al. (2020) · PubMed Central · Cited by 15
Self-citation
Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
Voutsadakis, I. A., & Digklia, A. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-22-108 · Cited by 16
New Insights into Tumor Heterogeneity: A Case of Solid-Oncocytic Epithelial-Myoepithelial Carcinoma of the Parotid Gland Harboring a HRAS and Heterogeneous Terminating ARID1A Mutation
Rupp, N. J., Brada, M. D., Skálová, A., Bode, B., Broglie, M. A., Morand, G. B., Rechsteiner, M., & Freiberger, S. N. (2019) · Head and Neck Pathology · doi:10.1007/s12105-019-01055-9 · Cited by 17
Therapeutic Application of PARP Inhibitors in Neuro-Oncology
Ning, J., & Wakimoto, H. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.004 · Cited by 16
The role of SWI/SNF chromatin remodelers in the repair of DNA double strand breaks and cancer therapy
Sadek, M., Sheth, A., Zimmerman, G., Hays, E., & Vélez-Cruz, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1071786 · Cited by 18
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system
Zimmer, K., Kocher, F., Untergasser, G., Kircher, B., Amann, A., Baca, Y., Xiu, J., Korn, W. M., Berger, M. D., Lenz, H., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00409-5 · Cited by 15
Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies
Hein, K. Z., Stephen, B., & Fu, S. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-37 · Cited by 17
ARID1A, a component of SWI/SNF chromatin remodeling complexes, is required for porcine embryo development
Tseng, Y., Cabot, B., & Cabot, R. A. (2017) · Molecular Reproduction and Development · doi:10.1002/mrd.22924 · Cited by 15
Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic
Gil, Y. R., Sánchez, P. J., Velasco, R. M., García, A. G., & Lobo, V. J. S.-A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042077 · Cited by 18
Tailored Therapy Based on Molecular Characteristics in Endometrial Cancer
Lee, S. (2021) · BioMed Research International · doi:10.1155/2021/2068023 · Cited by 15
Toward Targeted Therapies in Oesophageal Cancers: An Overview
Bregni, G., & Beck, B. (2022) · Cancers · doi:10.3390/cancers14061522 · Cited by 15
Novel approaches for treatment of endometrial carcinoma
Garg, V., Jayraj, A. S., & Kumar, L. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2022.100895 · Cited by 14
Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation
Stubbs, F. E., Flynn, B. P., Rivers, C. A., Birnie, M. T., Herman, A., Swinstead, E. E., Baek, S., Fang, H., Temple, J., Carroll, J. S., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02516-2 · Cited by 15
Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials
Karasic, T. B., Eads, J. R., & Goyal, L. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00573 · Cited by 13
The Role of the AT-Rich Interaction Domain 1A Gene (ARID1A) in Human Carcinogenesis
Li, J. J., & Lee, C. S. (2023) · Genes · doi:10.3390/genes15010005 · Cited by 15
A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations
Vogel, A., Haupts, A., Kloth, M. T., Roth, W., & Hartmann, N. (2024) · Diagnostic Pathology · doi:10.1186/s13000-023-01431-8 · Cited by 15
The interplay between chromatin remodeling and DNA double-strand break repair: Implications for cancer biology and therapeutics
He, L., Moon, J., Cai, C., Hao, Y., Lee, H., Kim, W., Zhao, F., & Lou, Z. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103811 · Cited by 15
Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets
Scholtes, M., Akbarzadeh, M., Γαλάρας, Α., Nakauma‐González, J. A., Bazrafshan, A., Solanki, V., Torenvliet, B., Beikmohammadi, L., Lozovanu, V., Romal, S., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217506 · Cited by 15
Pharmacoepigenomics
Cacabelos, R., & Torrellas, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00032-6 · Cited by 16
Protein‑loss of SWI/SNF‑complex core subunits influences prognosis dependent on histological subtypes of intra‑ and extrahepatic cholangiocarcinoma
Wagner, B. J., Plum, P. S., Apel, K., Scherer, M., Buchner, D., Brinkmann, S., Buettner, R., Stippel, D. L., Quaas, A., & Drebber, U. (2021) · Oncology Letters · doi:10.3892/ol.2021.12610 · Cited by 14
Molecular Characterization of Muellerian Tumors of the Urinary Tract
Ortiz‐Brüchle, N., Wucherpfennig, S., Rose, M., Garczyk, S., Bertz, S., Hartmann, A., Reis, H., Szarvas, T., Kiss, A., Bremmer, F., et al. (2021) · Genes · doi:10.3390/genes12060880 · Cited by 14
Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma
Huang, H.-J., Yang, L., Tung, H., Ku, F.-C., Wu, R., Tang, Y., Chang, W., Jung, S., Wang, C., Lin, C., et al. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.11.018 · Cited by 14
Self-citation
Remodeling of the ARID1A tumor suppressor
Luo, Q., Wu, X., & Liu, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.026 · Cited by 16
Self-citation
Role of SWI/SNF chromatin remodeling genes in lung cancer development
Monterde, B., & Varela, I. (2022) · Biochemical Society Transactions · doi:10.1042/bst20211084 · Cited by 13
Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications
Kim, H. K., & Kim, T. J. (2025) · Cells · doi:10.3390/cells14171404 · Cited by 13
PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production
Srinivas, U. S., Tay, N. S. C., Jaynes, P. W., Anbuselvan, A., Ramachandran, G. K., Wardyn, J. D., Hoppe, M. M., Hoang, P. M., Peng, Y., Lim, S., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02219-8 · Cited by 13
Self-citation
Research progress of SWI/SNF complex in breast cancer
Li, K., Wang, B., & Hu, H. (2024) · Epigenetics & Chromatin · doi:10.1186/s13072-024-00531-z · Cited by 14
Loss of ARID1A expression is associated with DNA mismatch repair protein deficiency and favorable prognosis in advanced stage surgically resected esophageal adenocarcinoma
Lowenthal, B. M., Nason, K. S., Pennathur, A., Luketich, J. D., Pai, R. K., Davison, J. M., & Ma, C. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.09.004 · Cited by 13
Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)
Hodroj, K., Stevovic, A., Attignon, V., Ferraioli, D., Méeus, P., Croce, S., Chopin, N., Rossi, L., Floquet, A., Rousset‐Jablonski, C., et al. (2021) · Cancers · doi:10.3390/cancers13020220 · Cited by 13
Relationship between cellular morphology and abnormality of SWI/SNF complex subunits in pancreatic undifferentiated carcinoma
Yamamoto, T., Kohashi, K., Yamada, Y., Kawata, J., Sakihama, K., Matsuda, R., Koga, Y., Aishima, S., Nakamura, M., & Oda, Y. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03860-8 · Cited by 13
Multidimensional chromatin profiling of zebrafish pancreas to uncover and investigate disease-relevant enhancers
Bordeira–Carriço, R., Teixeira, J., Duque, M., Galhardo, M., Ribeiro, D. M., Acemel, R. D., Firbas, P., Tena, J. J., Eufrásio, A., Marques, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29551-7 · Cited by 17
Differentially Expressed Genes and Signaling Pathways Potentially Involved in Primary Resistance to Chemo-Immunotherapy in Advanced-Stage Gastric Cancer Patients
Pinto, M. P., Muñoz‐Medel, M., Retamal, I. N., Bravo, M. L., Latapiat, V., Córdova‐Delgado, M., Hill, C. N., Fernández, M. F., Sánchez, C., Sáez, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010001 · Cited by 13
Natural product β-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy
Zhang, L., Peng, Y., Uray, I. P., Shen, J., Wang, L., Peng, X., Brown, P. H., Tu, W., & Peng, G. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.10.009 · Cited by 13
Self-citation
CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer
Chen, J.-Y., Ke, T.-W., Chiang, S., Hong, W.-Z., Chang, H.-Y., Liang, J. A., Tsai, Y., Huang, C.-H., Chen, W. T., Chao, K. S. C., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07912-6 · Cited by 12
Differences in DNA damage repair gene mutations between left‐ and right‐sided colorectal cancer
Huang, W., Li, W., Xu, N., Li, H., Zhang, Z., Zhang, X., He, T., Yao, J., Xu, M., He, Q., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5716 · Cited by 11
Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review
Mitranovici, M.-I., Chiorean, D. M., Moraru, L., Moraru, R., Caravia, L. G., Tiron, A. T., Cotoi, T. C., Toru, H. S., & Cotoi, O. S. (2024) · Pharmaceuticals · doi:10.3390/ph17030311 · Cited by 12
Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations
D’Ambrosio, A., Bressan, D., Ferracci, E., Carbone, F. G., Mulé, P., Rossi, F., Barbieri, C., Sorrenti, E., Fiaccadori, G., Detone, T., et al. (2024) · Science Advances · doi:10.1126/sciadv.adh4435 · Cited by 13
Epigenetic Control of Redox Pathways in Cancer Progression
Shah, V., Lam, H. Y., Leong, C. H.-M., Sakaizawa, R., Shah, J., & Kumar, A. P. (2025) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0465 · Cited by 12
Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy
Schnitzler, T., Ortiz‐Brüchle, N., Schneider, U., Lurje, I., Guricová, K., Büchner, A., Schulz, G. B., Heidenreich, A., Gaisa, N. T., Knüchel, R., et al. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00524-6 · Cited by 12
Targeting the BAF complex in advanced prostate cancer
Hartley, A., Leung, H. Y., & Ahmad, I. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1821644 · Cited by 12
Immunotherapy in rare ovarian cancer
Laga, T., Vergote, I. B., & Nieuwenhuysen, E. V. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000759 · Cited by 12
Downregulated ARID1A by miR-185 Is Associated With Poor Prognosis and Adverse Outcomes in Colon Adenocarcinoma
Baldi, S., Khamgan, H., Qian, Y., Wu, H., Zhang, Z., Zhang, M., Gao, Y., Safi, M., Alradhi, M., & Zuo, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679334 · Cited by 12
Brg1 is required to maintain colorectal cancer stem cells
Yoshikawa, T., Fukuda, A., Omatsu, M., Namikawa, M., Sono, M., Fukunaga, Y., Masuda, T., Araki, O., Nagao, M., Ogawa, S., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5759 · Cited by 12
Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells
Xing, B., Zhang, X., Gu, X., Xiang, L., Wang, C., & Jin, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05471-x · Cited by 11
Clinical outcome and molecular landscape of patients with ARID1A‐loss gastric cancer
Sun, M., Gu, Y., Fang, H., Shao, F., Lin, C., Zhang, H., He, L., He, H., Li, R., Wang, J., et al. (2023) · Cancer Science · doi:10.1111/cas.16057 · Cited by 11
The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers
Molefi, T., Mabonga, L., Hull, R., Mwazha, A., Sebitloane, M., & Dlamini, Z. (2025) · Cells · doi:10.3390/cells14050382 · Cited by 12
Anti-SARS-CoV-2 and anticancer properties of triptolide and its derived carbonized nanomaterials.
Kousar, R., Akhtar, T., Lin, C.-J., Lebedev, T. D., Li, Y.-C., Yang, C.-C., Wang, W.-J., Chen, H.-F., Su, W.-C., Biswas, P., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217677 · Cited by 10
Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
Sepe, P., Mennitto, A., Corti, F., & Procopio, G. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240889 · Cited by 11
ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report
Durán, M., Faull, I., Lastra, E., Laes, J., Rodrigo, A. B., & Sánchez-Escribano, R. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02589-1 · Cited by 11
Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations
Kurzrock, R., Aggarwal, C., Weipert, C. M., Kiedrowski, L. A., Riess, J. W., Lenz, H., & Gandara, D. R. (2022) · Cancers · doi:10.3390/cancers14174281 · Cited by 11

Authors: Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., Uray, I. P., Wu, X., Brown, P. H., Shen, X., Mills, G. B., & Peng, G.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
University of Pittsburgh (US)
Baylor College of Medicine (US)
Johns Hopkins University (US)
1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Corresponding author: Peng, Guang
ORCID: Shen, Jianfeng
Peng, Yang
Zhang, Wei
Yang, Lin
Lan, Li
Ju, Zhenlin
Mo, Qianxing
Shih, Ie-Ming
Wu, Xiangwei
Brown, Powel H.
Mills, Gordon B.
Peng, Guang
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-07-01
Volume: 5
Issue: 7
Pages: 752-767
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-14-0849
PMC: PMC4497871
OpenAlex: W2123454509
Cited by: 522
References: 61
Citations by year: 2026: 33 · 2025: 53 · 2024: 59 · 2023: 56 · 2022: 53 · 2021: 71 · 2020: 62 · 2019: 43 · 2018: 36 · 2017: 28 · 2016: 24 · 2015: 3
FWCI: 13.16
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (CA 016672, P50CA098258, P50-CA83639, R00CA149186, K99CA149186, P50CA083639, P30CA016672, R01CA181663)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords: ARID1A, SWI/SNF complex, DNA damage checkpoint, PARP inhibitors, ATR kinase, DNA double-strand breaks, tumor suppressor, drug sensitivity
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Breast Neoplasms, DNA Damage, DNA-Binding Proteins, Female, Humans, Lung Neoplasms, Male, Nuclear Proteins, Transcription Factors, Xenograft Model Antitumor Assays, HCT116 Cells, Cell Line, Tumor, Mice, DNA Breaks, Double-Stranded, Ataxia Telangiectasia Mutated Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks